Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Glucocorticoids are highly effective in the therapy of inflammatory and autoimmune disorders. Their beneficial action is restricted because of their adverse effects upon prolonged usage. Topical glucocorticoids that act locally have been developed to significantly reduce systemic side effects. Nonetheless, undesirable cutaneous effects such as skin atrophy persist from the use of topical glucocorticoids. There is therefore a high medical need for drugs as effective as glucocorticoids but with a reduced side‐effect profile. Glucocorticoids function by binding to and activating the glucocorticoid receptor that positively or negatively regulates the expression of specific genes. Several experiments suggest that the negative regulation of gene expression by the glucocorticoid receptor accounts for its anti‐inflammatory action. This occurs through direct or indirect binding of the receptor to transcription factors such as activator protein‐1, nuclear factor‐κ B or interferon regulatory factor‐3 that are already bound to their regulatory sites. The positive action of the receptor occurs through homodimer binding of the receptor to discrete nucleotide sequences and this possibly contributes to some of the adverse effects of the hormone. Glucocorticoid receptor ligands that promote the negative regulatory action of the receptor with reduced positive regulatory function should therefore show improved therapeutic potential. A complete separation of the positive from the negative regulatory activities of the receptor has so far not been possible because of the interdependent nature of the two regulatory processes. Nevertheless, considerable improvement in the therapeutic action of glucocorticoid receptor ligands is being achieved through the use of key molecular targets for screening novel glucocorticoid receptor ligands.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
DNA binding of the glucocorticoid receptor is not essential for survival
Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81183-6 · Cited by 1,068 · cited 3×
“In mice carrying the dimerization-defective GR mutant, the transactivation of several liver-specific genes was abolished or strongly reduced (24).”
BackgroundFunctional interactions between Stat5 and the glucocorticoid receptor
Stöcklin, E., Wissler, M., Gouilleux, F., & Groner, B. (1996) · Nature · doi:10.1038/383726a0 · Cited by 675 · cited 1×
“The ability of the GR to function as coactivator in the positive regulation of genes controlled by, for example, Stat5 is not affected by the dimerization and DNA-binding properties of the receptor (47).”
BackgroundMolecular determinants of crosstalk between nuclear receptors and toll-like receptors
Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R. K., Westin, S., Hoffmann, A., Subramaniam, S., David, M., Rosenfeld, M. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.06.029 · Cited by 647
Nissen, R. M., & Yamamoto, K. R. (2000) · Genes & Development · doi:10.1101/gad.827900 · Cited by 559 · cited 1×
“This occurs via competition of the GR with the CTD kinase positive transcription elongation factor-b (P-TEFb) for promoter binding (32,33).”
BackgroundHENCH, P. S. (1950) · Archives of Internal Medicine · doi:10.1001/archinte.1950.00230100002001 · Cited by 501 · cited 1×
“About 10 years later, it was shown to be effective in the treatment of rheumatoid arthritis, particularly when administered pharmacologically (3,4).”
BackgroundSchäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0300372101 · Cited by 466
Self-citationMAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock
Zhao, Q., Wang, X., Nelin, L. D., Yao, Y., Matta, R., Manson, M. E., Baliga, R. S., Meng, X., Smith, C. V., Bauer, J. A., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051794 · Cited by 370
Hammer, M., Mages, J., Dietrich, H., Servatius, A., Howells, N., Cato, A. C. B., & Lang, R. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051753 · Cited by 327
Self-citationWärnmark, A., Treuter, E., Wright, A. P. H., & Gustafsson, J.-A. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0384 · Cited by 308 · cited 2×
“Structurally, the GR consists of a C-terminal ligand-binding domain, a DNA-binding domain with a dimerization interface in the centre of the molecule and two transcriptional activation function (AF) domains AF-1 and AF-2 (22).”
BackgroundTuckermann, J. P., Reichardt, H. M., Arribas, R., Richter, K. H., Schütz, G., & Angel, P. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.147.7.1365 · Cited by 196 · cited 1×
“Other GR-regulated genes in skin such as Hsp 27 and plasma glutathione peroxidase were also not transcriptionally upregulated by GCs, demonstrating the need for GR dimerization for the expression of these genes (25).”
BackgroundThe GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression
Reily, M. M., Pantoja, C., Hu, X., Chinenov, Y., & Rogatsky, I. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7600919 · Cited by 149 · cited 5×
“The transcription factors to which the GR is tethered include activator protein-1 (AP-1), nuclear factor-jB (NF-jB) and interferon regulatory factor-3 (IRF-3) (27,28).”
BackgroundInfluentialEffects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
Humphrey, E. L., Williams, J. H. H., Davie, M. W. J., & Marshall, M. J. (2006) · Bone · doi:10.1016/j.bone.2005.10.004 · Cited by 139
Adams, M., Meijer, O. C., Wang, J., Bhargava, A., & Pearce, D. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0305 · Cited by 113 · cited 1×
“It is important to note that while some transactivation function of the GR may be destroyed by the dimerization mutation, there are clearly some genes positively regulated by the GR that are not affected by this mutation (46).”
Background
Cited by
Genomic and nongenomic effects of glucocorticoids
Stahn, C., & Buttgereit, F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0898 · Cited by 594
“IL-1, IL-2, tumor necrosis factor and interferon γ) and prostaglandins, is suppressed”
BackgroundVan Raalte, D. H., Ouwens, D. M., & Diamant, M. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02067.x · Cited by 439
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
Stahn, C., Löwenberg, M., Hommes, D. W., & Buttgereit, F. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.019 · Cited by 419
“Negative regulation by glucocorticoid/glucocorticoid receptor complexes results in reduced transcriptional activities of GCR target genes [19-23], leading to anti-inflammatory and immune-suppressive effects [24].”
BackgroundSheng, H., & Sun, H. (2011) · Natural Product Reports · doi:10.1039/c0np00059k · Cited by 289
Crosstalk between the glucocorticoid receptor and other transcription factors: Molecular aspects
Kassel, O., & Herrlich, P. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.07.003 · Cited by 277
“Notably, the so-called “dissociated” ligands or selective glucocorticoid receptor agonists (SEGRAs) have a reduced capacity to induce transcription while maintaining GR-mediated repression (reviewed in Miner, 2002; Schäcke et al., 2006).”
Background
Metadata
- Authors
- Schäcke, H., Rehwinkel, H., Asadullah, K., & Cato, A. C. B.
- Venue
- Experimental Dermatology
- Publisher
- Wiley
- Published
- 2006-06-30
- Volume
- 15
- Issue
- 8
- Pages
- 565-573
- ISSN
- 0906-6705 (ISSN-L)
- 1600-0625
- OpenAlex
- W2090821896
- Cited by
- 65
- References
- 14
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.